Antibiotic therapy of pneumonia in the obese patient: Dosing and delivery

Current Opinion in Infectious Diseases

Volumn 27, Issue 2, 2014, Pages 165-173

  Al Dorzi, Hasan M ^a,b   Al Harbi, Shmylan A ^a,b   Arabi, Yaseen M ^a,b  

^a KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^b KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

Author keywords

antibiotics; dosing; obesity; pharmacodynamics; pharmacokinetics

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; BETA LACTAM; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN; CEPHALOSPORIN DERIVATIVE; COLISTIMETHATE; COLISTIN; LINEZOLID; MACROLIDE; MEROPENEM; MOXIFLOXACIN; OSELTAMIVIR; PENICILLIN DERIVATIVE; PIPERACILLIN; POLYMYXIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SIALIDASE INHIBITOR; TAZOBACTAM; TIGECYCLINE; VANCOMYCIN; VORICONAZOLE;

ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; BARIATRIC SURGERY; BODY MASS; BODY WEIGHT; CHRONIC KIDNEY DISEASE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG METABOLISM; DRUG TREATMENT FAILURE; GLOMERULUS FILTRATION RATE; HUMAN; HYDROPHILICITY; KIDNEY CLEARANCE; KIDNEY FUNCTION; LIPOPHILICITY; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NEBULIZATION; OBESITY; OUTCOME ASSESSMENT; PHARMACOKINETICS; PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMONIA; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ROUX Y ANASTOMOSIS; STOMACH EMPTYING;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; HUMANS; OBESITY; PNEUMONIA;

EID: 84896719690     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000045     Document Type: Review

References (37)

1. Arabi YM, Dara SI, Tamim HM, et al. Clinical characteristics, sepsis interventions and outcomes in the obese patients with septic shock: an international multicenter cohort study. Crit Care 2013; 17:R72.
2. Roe JL, Fuentes JM, Mullins ME. Underdosing of common antibiotics for obese patients in the ED. Am J Emerg Med 2012; 30:1212-1214.
3. Longo C, Bartlett G, Macgibbon B, et al. The effect of obesity on antibiotic treatment failure: a historical cohort study. Pharmacoepidemiol Drug Saf 2013; 22:970-976.
4. Janson B, Thursky K. Dosing of antibiotics in obesity. Curr Opin Infect Dis 2012; 25:634-649.
5. Udy AA, Roberts JA, Lipman J. Clinical implications of antibiotic pharmacokinetic principles in the critically ill. Intensive Care Med 2013; 39:2070-2082.
6. Claus BO, Hoste EA, Colpaert K, et al. Augmented renal clearance is a common finding with worse clinical outcome in critically ill patients receiving antimicrobial therapy. J Crit Care 2013; 28:695-700.
7. Anderson AH, Yang W, Hsu CY, et al. Estimating GFR among participants in the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis 2012; 60:250-261.
8. Aggarwal N, Porter AC, Tang IY, et al. Creatinine-based estimations of kidney function are unreliable in obese kidney donors. J Transplant 2012; 2012: 872894.
9. Deman H, Verhaegen J, Willems L, Spriet I. Dosing of piperacillin/ tazobactam in a morbidly obese patient. J Antimicrob Chemother 2012; 67:782-783.
10. Cheatham SC, Fleming MR, Healy DP, et al. Steady-state pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese patients. Int J Antimicrob Agents 2013; 41: 52-56.
11. Rich BS, Keel R, Ho VP, et al. Cefepime dosing in the morbidly obese patient population. Obes Surg 2012; 22:465-471.
12. Cheatham SC, Fleming MR, Healy DP, et al. Steady-state pharmacokinetics and pharmacodynamics of meropenem in morbidly obese patients hospitalized in an intensive care unit. J Clin Pharmacol 2013. [Epub ahead of print]
13. Taccone FS, Cotton F, Roisin S, et al. Optimal meropenem concentrations to treat multidrug-resistant Pseudomonas aeruginosa septic shock. Antimicrob Agents Chemother 2012; 56:2129-2131.
14. Roberts JA, Lipman J. Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility. Crit Care Med 2013; 41:489-495.
15. Luque S, Grau S, Valle M, et al. Levofloxacin weight-adjusted dosing and pharmacokinetic disposition in a morbidly obese patient. J Antimicrob Chemother 2011; 66:1653-1654.
16. Cook AM, Martin C, Adams VR, Morehead RS. Pharmacokinetics of intravenous levofloxacin administered at 750 milligrams in obese adults. Antimicrob Agents Chemother 2011; 55:3240-3243.
17. Kees MG, Weber S, Kees F, Horbach T. Pharmacokinetics of moxifloxacin in plasma and tissue of morbidly obese patients. J Antimicrob Chemother 2011; 66:2330-2335.
18. Ross AL, Tharp JL, Hobbs GR, et al. Evaluation of extended interval dosing aminoglycosides in the morbidly obese population. Adv Pharmacol Sci 2013; 2013:194389.
19. Pai MP, Nafziger AN, Bertino JS Jr. Simplified estimation of aminoglycoside pharmacokinetics in underweight and obese adult patients. Antimicrob Agents Chemother 2011; 55:4006-4011.
20. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillinresistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011; 52:285-292.
21. Bhalodi AA, Papasavas PK, Tishler DS, et al. Pharmacokinetics of intravenous linezolid in moderately to morbidly obese adults. Antimicrob Agents Chemother 2013; 57:1144-1149.
22. Boselli E, Breilh D, Caillault-Sergent A, et al. Alveolar diffusion and pharmacokinetics of linezolid administered in continuous infusion to critically ill patients with ventilator-associated pneumonia. J Antimicrob Chemother 2012; 67:1207-1210.
23. Michalopoulos AS, Falagas ME. Colistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patients. Ann Intensive Care 2011; 1:30.
24. Mohamed AF, Karaiskos I, Plachouras D, et al. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother 2012; 56:4241-4249.
25. Koselke E, Kraft S, Smith J, Nagel J. Evaluation of the effect of obesity on voriconazole serum concentrations. J Antimicrob Chemother 2012; 67: 2957-2962.
26. Davies-Vorbrodt S, Ito JI, Tegtmeier BR, et al. Voriconazole serum concentrations in obese and overweight immunocompromised patients: a retrospective review. Pharmacotherapy 2013; 33:22-30.
27. Hoenigl M, Duettmann W, Raggam RB, et al. Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignancies. Antimicrob Agents Chemother 2013; 57:3262-3267.
28. O'Brien KB, Vogel P, Duan S, et al. Impaired wound healing predisposes obese mice to severe influenza virus infection. J Infect Dis 2012; 205:252-261.
29. Ariano RE, Sitar DS, Zelenitsky SA, et al. Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza. CMAJ 2010; 182:357-363.
30. Hites M, Taccone FS, Wolff F, et al. Case-control study of drug monitoring of beta-lactams in obese critically ill patients. Antimicrob Agents Chemother 2013; 57:708-715.
31. Taccone FS, Vincent JL, Denis O, Jacobs F. Should we abandon vancomycin for treatment of methicillin-resistant Staphylococcus aureus pneumonia? Still questions to answer. Clin Infect Dis 2012; 55:161-163; author reply 3-5.
32. Gauthier TP, Wolowich WR, Reddy A, et al. Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patients. Antimicrob Agents Chemother 2012; 56:2392-2396.
33. Lu Q, Yang J, Liu Z, et al. Nebulized ceftazidime and amikacin in ventilatorassociated pneumonia caused by Pseudomonas aeruginosa. Am J Respir Crit Care Med 2011; 184:106-115.
34. Tumbarello M, De Pascale G, Trecarichi EM, et al. Effect of aerosolized colistin as adjunctive treatment on the outcomes of microbiologically documented ventilator-associated pneumonia caused by colistin-only susceptible Gramnegative bacteria. Chest 2013; 144:1768-1775.
35. De Smet J, Colin P, De Paepe P, et al. Oral bioavailability of moxifloxacin after Roux-en-Y gastric bypass surgery. J Antimicrob Chemother 2012; 67:226-229.
36. Padwal RS, Ben-Eltriki M, Wang X, et al. Effect of gastric bypass surgery on azithromycin oral bioavailability. J Antimicrob Chemother 2012; 67:2203-2206.
37. Hamilton R, Thai XC, Ameri D, Pai MP. Oral bioavailability of linezolid before and after Roux-en-Y gastric bypass surgery: is dose modification necessary in obese subjects? J Antimicrob Chemother 2013; 68:666-673.